COST-EFFECTIVENESS ANALYSIS OF CAMRELIZUMAB VS. PLACEBO ADDED TO CHEMOTHERAPY AS FIRST-LINE THERAPY FOR ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINA
Account has been disabled due to a violation of Terms of Service. Contact Moderators
Account has been disabled due to a violation of Terms of Service. Contact Moderators